Related Experiment Video

Updated: Aug 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Immune-mediated rippling muscle disease

W J Schulte-Mattler1, R A Kley, E Rothenfusser-Korber

  • 1Department of Neurology, University of Regensburg, Germany.

Neurology
|January 26, 2005
PubMed

Insights

Rippling muscle disease (RMD) can occur without caveolin-3 gene mutations. This case study reveals reduced caveolin-3, altered dysferlin, and autoantibodies in RMD, suggesting broader autoimmune involvement in muscle disorders.

Area of Science:

  • Neurology
  • Muscle Biology
  • Immunology

Background:

  • Rippling muscle disease (RMD) is a rare neuromuscular disorder.
  • Mutations in the caveolin-3 gene are the most common cause of RMD.
  • The underlying pathophysiology of RMD in non-caveolin-3 mutation cases is not fully understood.

Observation:

  • A 44-year-old male patient presented with RMD.
  • The patient lacked mutations in the caveolin-3 gene.
  • Muscle biopsy revealed reduced caveolin-3 expression and a mosaic pattern of dysferlin.
  • Ultrastructural analysis showed loss of caveolae and triad alterations.

Findings:

  • The muscle biopsy demonstrated a marked reduction of caveolin-3.
  • Dysferlin immunostaining showed a mosaic pattern, indicating potential sarcolemmal defects.
  • Ultrastructural findings suggest disruption of sarcolemmal organization and T-tubule system.
  • Autoantibodies against the sarcolemma, triad, and unknown muscle proteins were detected.

Implications:

  • This case expands the known genetic and molecular basis of Rippling Muscle Disease.
  • The presence of autoantibodies suggests an autoimmune component in some RMD cases.
  • Understanding these alternative pathways is crucial for diagnosing and potentially treating RMD.
  • Further research into the identified autoantigens may reveal novel therapeutic targets for muscle disorders.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...